Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor

Le Wang, George Doherty, Andrew S. Judd, Zhi‐Fu Tao, Terkel Hansen, Robin R. Frey, Xiaohong Song, Milan Bruncko, Aaron Kunzer, Xilu Wang, Michael Wendt, John A. Flygare, Nathaniel D. Catron, Russell A. Judge, Chang H. Park, Shashank Shekhar, Darren C. Phillips, Paul Nimmer, Morey L. Smith, Stephen K. Tahir, Xiao Yu, John Xue, Haichao Zhang, Phuong N. Le, Michael J. Mitten, Erwin R. Boghaert, Wenqing Gao, Peter Kovar, Edna F. Choo, Dolores Diaz, Wayne J. Fairbrother, Steven W. Elmore, Deepak Sampath, Joel Johansson, Andrew J. SouersACS 2020 · DOI

Abstract

Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-X<sub>L</sub> inhibitor that selectively and potently induces apoptosis in BCL-X<sub>L</sub>-dependent tumor cells. This molecule was generated by re-engineering our previously reported BCL-X<sub>L</sub> inhibitor A-1155463 using structure-based drug design. Key design elements included rigidification of the A-1155463 pharmacophore and introduction of sp<sup>3</sup>-rich moieties capable of generating highly productive interactions within the key P4 pocket of BCL-X<sub>L</sub>. A-1331852 has since been used as a critical tool molecule for further exploring BCL-2 family protein biology, while also representing an attractive entry into a drug discovery program.
BibTeX
@inproceedings{wang2020discovery,
  author = {Le Wang and George Doherty and Andrew S. Judd and Zhi‐Fu Tao and Terkel Hansen and Robin R. Frey and Xiaohong Song and Milan Bruncko and Aaron Kunzer and Xilu Wang and Michael Wendt and John A. Flygare and Nathaniel D. Catron and Russell A. Judge and Chang H. Park and Shashank Shekhar and Darren C. Phillips and Paul Nimmer and Morey L. Smith and Stephen K. Tahir and Xiao Yu and John Xue and Haichao Zhang and Phuong N. Le and Michael J. Mitten and Erwin R. Boghaert and Wenqing Gao and Peter Kovar and Edna F. Choo and Dolores Diaz and Wayne J. Fairbrother and Steven W. Elmore and Deepak Sampath and Joel Johansson and Andrew J. Souers},
  title = {{Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> Inhibitor}},
  booktitle = {ACS},
  year = {2020},
  doi = {10.1021/acsmedchemlett.9b00568},
}

Loading related content...

Figure